NASDAQ:UBX - Unity Biotechnology Stock Price, Forecast & News

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Unity Biotechnology Inc (NASDAQ:UBX) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.05. View Unity Biotechnology's Earnings History.

Unity Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Unity Biotechnology.

3 brokerages have issued 12-month price targets for Unity Biotechnology's stock. Their forecasts range from $14.00 to $33.00. On average, they anticipate Unity Biotechnology's stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 202.2% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.

Headlines about UBX stock have been trending somewhat positive on Friday, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Unity Biotechnology.

Unity Biotechnology saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 4,800,000 shares, an increase of 5.7% from the November 28th total of 4,540,000 shares. Based on an average trading volume of 260,400 shares, the short-interest ratio is currently 18.4 days. Currently, 22.5% of the company's shares are sold short. View Unity Biotechnology's Current Options Chain.

Some companies that are related to Unity Biotechnology include BELLUS Health (BLUSF), Atrion (ATRI), National HealthCare (NHC), Madrigal Pharmaceuticals (MDGL), Clinigen Group (CLIN), Endonovo Therapeutics (ENDV), Y-mAbs Therapeutics (YMAB), Health Catalyst (HCAT), Aphria (APHA), Sienna Senior Living (SIA), Mesoblast (MSB), Silk Road Medical (SILK), Zealand Pharma Aktieselskabet (ZLDPF), Supernus Pharmaceuticals (SUPN) and Shockwave Medical (SWAV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), JD.Com (JD), NIO (NIO), Cisco Systems (CSCO), Alibaba Group (BABA), Baidu (BIDU), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), NVIDIA (NVDA) and SmileDirectClub (SDC).

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UBX stock can currently be purchased for approximately $7.39.

Unity Biotechnology has a market capitalization of $339.51 million. Unity Biotechnology employs 106 workers across the globe.View Additional Information About Unity Biotechnology.